University of Sussex
Browse
RazorMain draft RV1clean for SRO.pdf (410.07 kB)

RAZOR: a phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in premenopausal women at increased risk of breast cancer

Download (410.07 kB)
journal contribution
posted on 2023-06-09, 13:16 authored by Anthony Howell, Linda Ashcroft, Lesley FallowfieldLesley Fallowfield, Diana M Eccles, Rosalind A Eeles, Anne Ward, Adam R Brentnall, Mitchell Dowsett, Jack M Cuzick, Rosemary Greenhalgh, Caroline Boggis, Jamie Motion, Jamie C Sergeant, Judith Adams, D Gareth Evans
Background: Ovarian suppression in premenopausal women is known to reduce breast cancer risk. This study aimed to assess uptake and compliance with ovarian suppression using the luteinizing hormone releasing hormone (LHRH) analogue, goserelin, with add-back raloxifene, as a potential regimen for breast cancer prevention.Methods: Women at >/=30% lifetime risk breast cancer were approached and randomized to mammographic screening alone (C-Control) or screening in addition to monthly subcutaneous injections of 3.6 mg goserelin and continuous 60 mg raloxifene daily orally (T-Treated) for 2 years. The primary endpoint was therapy adherence. Secondary endpoints were toxicity/quality of life, change in bone density, and mammographic density.Results: A total of 75/950 (7.9%) women approached agreed to randomization. In the T-arm, 20 of 38 (52%) of women completed the 2-year period of study compared with the C-arm (27/37, 73.0%). Dropouts were related to toxicity but also the wish to have established risk-reducing procedures and proven chemoprevention. As relatively few women completed the study, data are limited, but those in the T-arm reported significant increases in toxicity and sexual problems, no change in anxiety, and less cancer worry. Lumbar spine bone density declined by 7.0% and visually assessed mammographic density by 4.7% over the 2-year treatment period.Conclusions: Uptake is somewhat lower than comparable studies with tamoxifen for prevention with higher dropout rates. Raloxifene may preserve bone density, but reduction in mammographic density reversed after treatment was completed.Impact: This study indicates that breast cancer risk reduction may be possible using LHRH agonists, but reducing toxicity and preventing bone changes would make this a more attractive option. Cancer Epidemiol Biomarkers Prev; 27(1); 58-66. (c)2017 AACR.

Funding

Eli Lilly

Astrazeneca

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Cancer Epidemiology Biomarkers & Prevention (CEBP)

ISSN

1055-9965

Publisher

American Association for Cancer Research

Issue

1

Volume

27

Page range

58-66

Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2018-05-15

First Open Access (FOA) Date

2018-11-02

First Compliant Deposit (FCD) Date

2018-05-11

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC